Page 10 - Evaluate Efficacy News Today

Share this article NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). 1 These data build on previously announced Phase 3 topline ...

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients - 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p 0.001)[1] - All ranked secondary endpoints were met[1] - These results reaffirm findings from the first Phase 3 induction study, U-ACHIEVE[1,2] - Safety results were consistent wi...

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults* January 29, 2021 12:20 ET | Source: Arvelle Therapeutics Arvelle Therapeutics Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom ZUG,...

European Commission Approves AbbVies RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2] - Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RI...

Press release content from Business Wire. The AP news staff was not involved in its creation. AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients January 21, 2021 GMT SEONGNAM, South Korea--(BUSINESS WIRE)--Jan 21, 2021-- AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21 st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR10...

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments - Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million - Angelini Pharma will become a leading player amongst companies focused on Central Nervous System (CNS) and mental health disorder treatments - Opening direct affiliates in France, UK, Nordics and S...

There is particular interest in monoclonal antibody agents to determine whether their immune suppressive effects can reduce the immediate and long-term impact of COVID-19.

ABBVie today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib achieved superiority to dupilumab for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index at week 16, in adults with moderate to severe atopic dermatitis. 1 Of patients treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 … ABBVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads...

RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis - 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1] - Upadacitinib showed superiority versus dupilumab for all ranked secondary endpoints, including early improvements in itch and skin clear...